We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Daiichi Sankyo Company announced it is making an initial 15 billion yen investment to optimize and enhance its manufacturing capabilities to support its antibody drug conjugate (ADC) pipeline.